We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Consensus PT $833.31 · 28 analysts
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
An insider trade (Form 4) was filed.
Stored first · Google News · Yahoo Finance (English)
Regeneron (REGN) Down 12.1% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Regeneron (REGN) Down 12.1% Since Last Earnings Report: Can It Rebound? Yahoo Finance
National Pension Service Acquires 82,853 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
National Pension Service Acquires 82,853 Shares of Regeneron Pharmaceuticals, Inc. $REGN MarketBeat
Regeneron Pharmaceuticals (REGN) Receives WHO Approval for Ebola Treatment - GuruFocus
Regeneron Pharmaceuticals (REGN) Receives WHO Approval for Ebola Treatment GuruFocus
Regeneron (REGN) Advances Maftivimab for Ebola Treatment Trials - GuruFocus
Regeneron (REGN) Advances Maftivimab for Ebola Treatment Trials GuruFocus
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 07. 30. | After market close (AMC) | $10.85 | — | — | $3.81B | — | Scheduled |
| FY2026 Q1 | 2026. 04. 29. | Time TBD | — | $7.27 | — | — | $3.03B | Reported |
| FY2025 Q3 | 2025. 10. 28. | Time TBD | — | $30.23 | — | — | $10.41B | Reported |
| FY2025 Q2 | 2025. 08. 01. | Time TBD | — | $18.68 | — | — | $6.69B | Reported |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2026. 05. 19. | Canaccord Genuity | — | Maintain | Buy → Buy | — | Canaccord Genuity: Buy |
| 2026. 05. 19. | BMO Capital | — | Maintain | Outperform → Outperform | — | BMO Capital: Outperform |
| 2026. 05. 19. | Truist Securities | — | Maintain | Buy → Buy | — | Truist Securities: Buy |
| 2026. 05. 18. | JP Morgan | — | Maintain | Overweight → Overweight | — | JP Morgan: Overweight |
| 2026. 05. 18. | Piper Sandler | — | Maintain | Overweight → Overweight | — | Piper Sandler: Overweight |
| 2026. 05. 18. | Wells Fargo | — | Maintain | Equal-Weight → Equal-Weight | — | Wells Fargo: Equal-Weight |
As of FY2026Q1 · Source: SEC/DART + price data
| # | Institution | Mandate | Shares | Value | Weight | Change | Position |
|---|---|---|---|---|---|---|---|
| 1 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 812,236 | $627.57B | 0.54% | — | New position |
| 2 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 281,151 | $217.01B | 0.34% | — | New position |
| 3 | Point72 Asset Management, L.P. | Point72 Asset Management, L.P. | 262,527 | $202.64B | 0.33% | — | New position |
| 4 | Point72 Asset Management, L.P. | Point72 Asset Management, L.P. | 2,175 | $1.68B | 0.00% | — | New position |